COAG - Company ID 0002114044
Hemab Therapeutics Holdings, Inc. trades as COAG and has a market capitalization of $1.74 B, making it the #2257 largest US-listed company by market value. This page tracks Hemab Therapeutics Holdings, Inc. through 38 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-21 |
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-14 |
| New insider ownership | 3 | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| SCHEDULE 13D | - | 2026-05-11 |
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders · Advancing ...
The largest companies sharing Hemab Therapeutics Holdings, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalization of $1.74 B as of 2026-07-09, ranking #2257 among US-listed companies.